FindTrial
Sign In

Encaleret

DRUG5 trials

Sponsors

Calcilytix Therapeutics, Inc., a BridgeBio company, National Institute of Dental and Craniofacial Research (NIDCR)

Conditions

Autosomal Dominant Hypocalcemia (ADH)Autosomal Dominant Hypocalcemia Type 1 (ADH1)Chronic HypoparathyroidismHypoparathyroidismPost-Surgical Hypoparathyroidism

Phase 2

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
CompletedNCT04581629
Calcilytix Therapeutics, Inc., a BridgeBio companyAutosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Start: 2020-09-20End: 2023-09-07Updated: 2024-11-19
PTH-independent Effects of Encaleret
CompletedNCT05735015
National Institute of Dental and Craniofacial Research (NIDCR)Post-Surgical Hypoparathyroidism
Start: 2023-09-01End: 2025-08-12Updated: 2026-03-11
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
RecruitingNCT07080385
Calcilytix Therapeutics, Inc., a BridgeBio companyAutosomal Dominant Hypocalcemia Type 1 (ADH1)
Start: 2026-01-30End: 2030-12-01Target: 28Updated: 2026-04-22

Phase 3

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Active, not recruitingNCT05680818
Calcilytix Therapeutics, Inc., a BridgeBio companyAutosomal Dominant Hypocalcemia (ADH)
Start: 2023-01-06End: 2029-08-01Updated: 2026-07-29
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
RecruitingNCT07805356
Calcilytix Therapeutics, Inc., a BridgeBio companyChronic Hypoparathyroidism, Hypoparathyroidism
Start: 2026-08-31End: 2033-01-01Target: 160Updated: 2026-09-16

Related Papers

SAT-746 Gain-of-Function CASR variants Identified as a Major Genetic Contributor of Non-Surgical Hypoparathyroidism: Findings from Over 300 Participants in a Sponsored Genetic Testing Program
Journal of the Endocrine Society2025-10-01
SUN-777 CALIBRATE-PEDS: A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants with Autosomal Dominant Hypocalcemia Type1
Journal of the Endocrine Society2025-10-01
OR36-06 Sustained Normalization of Mineral Homeostasis in Autosomal Dominant Hypocalcemia Type 1: Results from a Phase 2 Study Over 42 Months of Encaleret (CLTX-305) Treatment
Journal of the Endocrine Society2025-10-01
12520 Preliminary Findings From An Ongoing Open-label Phase 2 Study Demonstrate That The Calcilytic Encaleret Can Improve The Relationship Between Blood And Urinary Calcium In Individuals With Post-surgical Hypoparathyroidism
Journal of the Endocrine Society2024-10-011 citations
Abstract 14476: Effects of Encaleret on Corrected QT Interval in Autosomal Dominant Hypocalcemia Type 1: Early Results From an Ongoing Phase 2b, Open-Label, Dose-Ranging Study
Circulation2021-11-161 citations
The Effects of Encaleret (CLTX-305) on Mineral Physiology in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrate Proof-of-Concept: Early Results From an Ongoing Phase 2b, Open-Label, Dose-Ranging Study
Journal of the Endocrine Society2021-05-015 citations
A Phase 2B, Open-Label, Dose-Ranging Study of Encaleret (CLTX-305) in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Journal of the Endocrine Society2021-05-011 citations